Latest ORBIMED ADVISORS LLC Stock Portfolio
ORBIMED ADVISORS LLC Performance:
2025 Q3: 5.6%YTD: -0.26%2024: 10.75%
Performance for 2025 Q3 is 5.6%, and YTD is -0.26%, and 2024 is 10.75%.
About ORBIMED ADVISORS LLC and 13F Hedge Fund Stock Holdings
ORBIMED ADVISORS LLC is a hedge fund based in NEW YORK, NY. On 29-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $18.3 Billions. In it's latest 13F Holdings report, ORBIMED ADVISORS LLC reported an equity portfolio of $4.3 Billions as of 30 Sep, 2025.
The top stock holdings of ORBIMED ADVISORS LLC are EWTX, BSX, LLY. The fund has invested 5.9% of it's portfolio in EDGEWISE THERAPEUTICS INC and 5.6% of portfolio in BOSTON SCIENTIFIC CORP.
The fund managers got completely rid off VERTEX PHARMACEUTICALS INC (VRTX), TENET HEALTHCARE CORP (THC) and CYTOKINETICS INC (CYTK) stocks. They significantly reduced their stock positions in XENON PHARMACEUTICALS INC (XENE), PRELUDE THERAPEUTICS INC and RAPT THERAPEUTICS INC (RAPT). ORBIMED ADVISORS LLC opened new stock positions in DANAHER CORPORATION (DHR), UNITED THERAPEUTICS CORP DEL (UTHR) and THE CIGNA GROUP (CI). The fund showed a lot of confidence in some stocks as they added substantially to KRYSTAL BIOTECH INC (KRYS), ASCENDIS PHARMA A/S and ORIC PHARMACEUTICALS INC (ORIC).
The top stock holdings of ORBIMED ADVISORS LLC are EWTX, BSX, LLY. The fund has invested 5.9% of it's portfolio in EDGEWISE THERAPEUTICS INC and 5.6% of portfolio in BOSTON SCIENTIFIC CORP.
The fund managers got completely rid off VERTEX PHARMACEUTICALS INC (VRTX), TENET HEALTHCARE CORP (THC) and CYTOKINETICS INC (CYTK) stocks. They significantly reduced their stock positions in XENON PHARMACEUTICALS INC (XENE), PRELUDE THERAPEUTICS INC and RAPT THERAPEUTICS INC (RAPT). ORBIMED ADVISORS LLC opened new stock positions in DANAHER CORPORATION (DHR), UNITED THERAPEUTICS CORP DEL (UTHR) and THE CIGNA GROUP (CI). The fund showed a lot of confidence in some stocks as they added substantially to KRYSTAL BIOTECH INC (KRYS), ASCENDIS PHARMA A/S and ORIC PHARMACEUTICALS INC (ORIC).
ORBIMED ADVISORS LLC Annual Return Estimates Vs S&P 500
Our best estimate is that ORBIMED ADVISORS LLC made a return of 5.6% in the last quarter. In trailing 12 months, it's portfolio return was -6.2%.
New Buys
| Ticker | $ Bought |
|---|---|
| danaher corporation | 52,162,200 |
| united therapeutics corp del | 48,167,200 |
| the cigna group | 46,927,100 |
| abivax sa | 32,262,000 |
| uniqure nv | 26,762,600 |
| eyepoint pharmaceuticals inc | 25,575,000 |
| carlsmed inc | 16,772,300 |
| shattuck labs inc | 15,071,600 |
New stocks bought by ORBIMED ADVISORS LLC
Additions
| Ticker | % Inc. |
|---|---|
| krystal biotech inc | 1,016 |
| ascendis pharma a/s | 457 |
| oric pharmaceuticals inc | 304 |
| akero therapeutics inc | 149 |
| amylyx pharmaceuticals inc | 139 |
| dyne therapeutics inc | 124 |
| mineralys therapeutics inc | 93.27 |
| exact sciences corp | 63.77 |
Additions to existing portfolio by ORBIMED ADVISORS LLC
Reductions
| Ticker | % Reduced |
|---|---|
| xenon pharmaceuticals inc | -55.73 |
| prelude therapeutics inc | -48.45 |
| immatics n.v | -35.19 |
| rapt therapeutics inc | -33.82 |
| integer hldgs corp | -33.09 |
| amicus therapeutics inc | -28.00 |
| natera inc | -27.66 |
| c4 therapeutics inc | -23.35 |
ORBIMED ADVISORS LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| third harmonic bio inc | -31,380,400 |
| abcellera biologics inc | -11,471,900 |
| turnstone biologics corp | -1,112,640 |
| cytokinetics inc | -35,584,100 |
| chemomab therapeutics ltd | -1,091,550 |
| tyra biosciences inc | -7,700,050 |
| iteos therapeutics inc | -6,979,000 |
| engene holdings inc | -2,467,840 |
ORBIMED ADVISORS LLC got rid off the above stocks
Sector Distribution
ORBIMED ADVISORS LLC has about 66.8% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 66.8 |
| Others | 31.2 |
| 2 |
Market Cap. Distribution
ORBIMED ADVISORS LLC has about 32.2% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 31.8 |
| LARGE-CAP | 26.1 |
| SMALL-CAP | 16.2 |
| MID-CAP | 10.7 |
| MICRO-CAP | 7.8 |
| MEGA-CAP | 6.1 |
| NANO-CAP | 1.2 |
Stocks belong to which Index?
About 49% of the stocks held by ORBIMED ADVISORS LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 50.9 |
| RUSSELL 2000 | 25.5 |
| S&P 500 | 23.5 |
ORBIMED ADVISORS LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of ORBIMED ADVISORS LLC
ORBIMED ADVISORS LLC has 98 stocks in it's portfolio. About 40.5% of the portfolio is in top 10 stocks. SBTX proved to be the most loss making stock for the portfolio. EWTX was the most profitable stock for ORBIMED ADVISORS LLC last quarter.
Last Reported on: 14 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AADI | whitehawk therapeutics inc | 0.19 | 4,166,000 | 7,915,400 | unchanged | 0.00 | ||
| ABCL | abcellera biologics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ACET | adicet bio inc | 0.22 | 11,447,100 | 9,274,470 | unchanged | 0.00 | ||
| ADCT | adc therapeutics sa | 0.56 | 5,907,350 | 23,629,400 | unchanged | 0.00 | ||
| AGIO | agios pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AKRO | akero therapeutics inc | 0.59 | 526,200 | 24,984,000 | added | 149 | ||
| ALNY | alnylam pharmaceuticals inc | 3.23 | 301,600 | 137,530,000 | reduced | -11.79 | ||
| AMLX | amylyx pharmaceuticals inc | 0.24 | 750,600 | 10,200,700 | added | 139 | ||
| APLS | apellis pharmaceuticals inc | 1.24 | 2,323,370 | 52,577,800 | added | 56.74 | ||
| ATAI | atai life sciences nv | 0.04 | 347,000 | 1,835,630 | new | |||
| AVTE | jade biosciences inc | 0.11 | 531,163 | 4,583,940 | unchanged | 0.00 | ||
| AVTX | avalo therapeutics inc | 0.40 | 1,349,300 | 17,149,600 | added | 39.53 | ||
| AXSM | axsome therapeutics inc | 1.52 | 531,800 | 64,587,100 | added | 24.28 | ||
| BCRX | biocryst pharmaceuticals inc | 0.16 | 901,500 | 6,842,380 | new | |||
| BSX | boston scientific corp | 5.57 | 2,429,300 | 237,173,000 | reduced | -13.65 | ||
| CCCC | c4 therapeutics inc | 0.27 | 5,235,150 | 11,622,000 | reduced | -23.35 | ||
| CELC | celcuity inc | 0.10 | 84,020 | 4,150,590 | new | |||
| CELC | celcuity inc | 0.06 | 2,000,000 | 2,684,240 | new | |||
| CGEM | cullinan therapeutics inc | 0.27 | 1,923,860 | 11,408,500 | unchanged | 0.00 | ||
| CI | the cigna group | 1.10 | 162,800 | 46,927,100 | new | |||